search
Back to results

CERAB Technique for Aortoiliac Occlusive Disease

Primary Purpose

Aortoiliac Occlusive Disease

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Covered Endovacular Reconstruction of Aortic Bifurcation
Sponsored by
Assiut University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Aortoiliac Occlusive Disease

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age: 18 years and older patients.
  2. Patient presented with disabling claudication pain.
  3. Patient presented with rest pain.
  4. Patient presented with gangrene or atrophic changes.
  5. Provided written informed consent.
  6. Eligible anatomy for CERAB technique.
  7. TASC- (II) classification as assigned in the study protocol (specified type B, C and D lesions).

Exclusion Criteria:

  1. Age less than 18 years old.
  2. Patients with acute limb ischemia.
  3. Patients treated with open surgery and other endovascular techniques such as kissing stenting.
  4. CERAB configuration extending into aneurysmatic infrarenal aorta.
  5. Patient's life expectancy <2 years as judged by the investigator.
  6. Patient has a psychiatric or other condition that may interfere with the study.
  7. Patient has a known allergy to any device component.
  8. Patients with a systemic infection who may be at increased risk of endovascular graft infection.
  9. Patient has a coagulopathy or uncontrolled bleeding disorder.
  10. Patient had a recent cerebrovascular accident (CVA) or a myocardial infarction (MI) within the prior three months.
  11. Patient is pregnant (Female patients of childbearing potential only).

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Other

    Arm Label

    Aortoiliac occlusive disease

    Arm Description

    This study will be carried out on patients with extensive Aortoiliac occlusive disease using the CERAB technique.

    Outcomes

    Primary Outcome Measures

    Primary patency
    uninterrupted patency in the absence of re-stenosis or occlusion, without any procedures performed on the vessel or stent.
    Technical success
    successful implantation of the CERAB device restoring blood flow with <30% residual stenosis without conversion to open repair during the 30-days after implantation

    Secondary Outcome Measures

    Secondary patency
    patency achieved by all procedures aimed at recanalizing an occluded CBES, thereby preserving the endograft.
    Freedom from target lesion revascularization (TLR)
    an open endograft without procedures performed for re-stenosis or occlusion leading to symptoms requiring an intervention.
    Clinical improvement
    hemodynamic improvement with an increase of at least 0.10 in ABI, combined with a symptomatic improvement of at least one Rutherford category.
    Re-stenosis
    a lesion with a peak systolic value (PSV) ratio >2.5 as measured in the endograft and proximal or distal to the endograft or an angiographic diameter reduction of >50%.
    Limb salvage rate
    all patients without above ankle amputations
    Minor complications
    those that were only temporary leading to impairment, whereas major complications were defined by permanent damage or death.

    Full Information

    First Posted
    October 30, 2019
    Last Updated
    July 10, 2020
    Sponsor
    Assiut University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04148456
    Brief Title
    CERAB Technique for Aortoiliac Occlusive Disease
    Official Title
    Covered Endovascular Reconstruction of Aortic Bifurcation (CERAB) Technique for Extensive Aortoiliac Occlusive Disease
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2020
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    January 1, 2021 (Anticipated)
    Primary Completion Date
    December 1, 2023 (Anticipated)
    Study Completion Date
    January 1, 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Assiut University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    To evaluate the safety and efficacy of the CERAB technique as an alternative to surgical reconstruction for treatment of aorto-iliac occlusive disease.
    Detailed Description
    According to the Trans-Atlantic Inter-society Consensus (TASC-II), bypass grafting is the treatment of choice for extensive aortoiliac occlusive disease (AIOD) due to the good long-term patency rates. However, surgical reconstruction is associated with peri-operative morbidity and mortality. Kissing stent technique was introduced as an endovascular treatment alternative for bilateral aortoiliac occlusive disease in 1991. Reported technical success rates varied with the use of bare metal stents in extensive AOID. The COBEST trial showed that covered balloon expandable stents (CBES) have a superior primary patency rate and clinical improvement outcome at 24 months when compared with bare metal stents. CBES may immediately reduce the risk of procedural complications such as dissection, perforation, in-stent stenosis, and embolization. In 2013, CERAB technique was introduced to improve endovascular treatment results by a more anatomical and physiological reconstruction, with a subsequent better clinical outcome. The CERAB technique was developed to overcome the anatomical and physiological disadvantages of kissing stents such as flow disturbances leading to turbulence and stasis of blood, which may cause thrombus formation and intimal neohyperplasia. The early results of the CERAB configuration are promising at 1-year follow up in a group of 130 patients with AOID and the 30-day major complication rate was 7.7%. CERAB and Chimney CERAB (C-CERAB) techniques may change the treatment algorithm of AIOD and juxta-renal occlusive disease. It appears to be a safe and feasible alternative with promising results, being a valid alternative for surgery and/or kissing stents.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Aortoiliac Occlusive Disease

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    53 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Aortoiliac occlusive disease
    Arm Type
    Other
    Arm Description
    This study will be carried out on patients with extensive Aortoiliac occlusive disease using the CERAB technique.
    Intervention Type
    Procedure
    Intervention Name(s)
    Covered Endovacular Reconstruction of Aortic Bifurcation
    Intervention Description
    The occlusive lesion is then passed, either subintimal or endoluminal, using crossing wires and catheters. After gaining re-entry into the lumen of the aorta, angiography will be confirmed proper positioning for those with a subintimal passage. A 10-12 mm V12 LD balloon expandable ePTFE covered stent (Atrium Medical, Maquet Getinge Group, Hudson, NH) will be expanded in the distal aorta approximately 20 mm above the bifurcation through the 9 Fr sheath. The proximal 2/3 part of the aortic stent will be flared with a larger balloon, usually 16 mm, thereby creating a funnel shaped covered stent. Subsequently, two 8 mm V12 balloon expandable ePTFE covered stents (Atrium Medical, Maquet Getinge Group, Hudson, NH) will be placed proximally in the distal 1/3 of the aortic stent, and then simultaneously deployed distally into the common iliac arteries creating a tight connection with the first aortic stent, thereby creating the new aortic bifurcation.
    Primary Outcome Measure Information:
    Title
    Primary patency
    Description
    uninterrupted patency in the absence of re-stenosis or occlusion, without any procedures performed on the vessel or stent.
    Time Frame
    12 months
    Title
    Technical success
    Description
    successful implantation of the CERAB device restoring blood flow with <30% residual stenosis without conversion to open repair during the 30-days after implantation
    Time Frame
    1 month
    Secondary Outcome Measure Information:
    Title
    Secondary patency
    Description
    patency achieved by all procedures aimed at recanalizing an occluded CBES, thereby preserving the endograft.
    Time Frame
    12 months
    Title
    Freedom from target lesion revascularization (TLR)
    Description
    an open endograft without procedures performed for re-stenosis or occlusion leading to symptoms requiring an intervention.
    Time Frame
    12 months
    Title
    Clinical improvement
    Description
    hemodynamic improvement with an increase of at least 0.10 in ABI, combined with a symptomatic improvement of at least one Rutherford category.
    Time Frame
    12 months
    Title
    Re-stenosis
    Description
    a lesion with a peak systolic value (PSV) ratio >2.5 as measured in the endograft and proximal or distal to the endograft or an angiographic diameter reduction of >50%.
    Time Frame
    12 months
    Title
    Limb salvage rate
    Description
    all patients without above ankle amputations
    Time Frame
    12 months
    Title
    Minor complications
    Description
    those that were only temporary leading to impairment, whereas major complications were defined by permanent damage or death.
    Time Frame
    12 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age: 18 years and older patients. Patient presented with disabling claudication pain. Patient presented with rest pain. Patient presented with gangrene or atrophic changes. Provided written informed consent. Eligible anatomy for CERAB technique. TASC- (II) classification as assigned in the study protocol (specified type B, C and D lesions). Exclusion Criteria: Age less than 18 years old. Patients with acute limb ischemia. Patients treated with open surgery and other endovascular techniques such as kissing stenting. CERAB configuration extending into aneurysmatic infrarenal aorta. Patient's life expectancy <2 years as judged by the investigator. Patient has a psychiatric or other condition that may interfere with the study. Patient has a known allergy to any device component. Patients with a systemic infection who may be at increased risk of endovascular graft infection. Patient has a coagulopathy or uncontrolled bleeding disorder. Patient had a recent cerebrovascular accident (CVA) or a myocardial infarction (MI) within the prior three months. Patient is pregnant (Female patients of childbearing potential only).
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    omar M Abd Elhakam, Doctor
    Phone
    01064991946
    Email
    omarhejazy@ymail.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    omar M Abd Elhakam, Doctor
    Organizational Affiliation
    Assiut University
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Ayman E Hassaballah, Professor
    Organizational Affiliation
    Assiut University
    Official's Role
    Study Director
    First Name & Middle Initial & Last Name & Degree
    Haitham A Hassan, Doctor
    Organizational Affiliation
    Assiut University
    Official's Role
    Study Chair
    First Name & Middle Initial & Last Name & Degree
    Ahmed K Sayed, Doctor
    Organizational Affiliation
    Assiut University
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    17223489
    Citation
    Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007 Jan;45 Suppl S:S5-67. doi: 10.1016/j.jvs.2006.12.037. No abstract available.
    Results Reference
    background
    PubMed Identifier
    1878908
    Citation
    Kuffer G, Spengel F, Steckmeier B. Percutaneous reconstruction of the aortic bifurcation with Palmaz stents: case report. Cardiovasc Intervent Radiol. 1991 May-Jun;14(3):170-2. doi: 10.1007/BF02577722. No abstract available.
    Results Reference
    background
    PubMed Identifier
    22695260
    Citation
    Grimme FA, Goverde PA, Van Oostayen JA, Zeebregts CJ, Reijnen MM. Covered stents for aortoiliac reconstruction of chronic occlusive lesions. J Cardiovasc Surg (Torino). 2012 Jun;53(3):279-89.
    Results Reference
    background
    PubMed Identifier
    17308516
    Citation
    Bosiers M, Iyer V, Deloose K, Verbist J, Peeters P. Flemish experience using the Advanta V12 stent-graft for the treatment of iliac artery occlusive disease. J Cardiovasc Surg (Torino). 2007 Feb;48(1):7-12.
    Results Reference
    background
    PubMed Identifier
    23210879
    Citation
    Grimme FA, Spithoven JH, Zeebregts CJ, Scharn DM, Reijnen MM. Midterm outcome of balloon-expandable polytetrafluoroethylene-covered stents in the treatment of iliac artery chronic occlusive disease. J Endovasc Ther. 2012 Dec;19(6):797-804. doi: 10.1583/JEVT-12-3941MR.1.
    Results Reference
    background
    PubMed Identifier
    25218651
    Citation
    Grimme FA, Reijnen MM, Pfister K, Martens JM, Kasprzak P. Polytetrafluoroethylene covered stent placement for focal occlusive disease of the infrarenal aorta. Eur J Vasc Endovasc Surg. 2014 Nov;48(5):545-50. doi: 10.1016/j.ejvs.2014.08.009. Epub 2014 Sep 11.
    Results Reference
    background
    PubMed Identifier
    20538478
    Citation
    Sabri SS, Choudhri A, Orgera G, Arslan B, Turba UC, Harthun NL, Hagspiel KD, Matsumoto AH, Angle JF. Outcomes of covered kissing stent placement compared with bare metal stent placement in the treatment of atherosclerotic occlusive disease at the aortic bifurcation. J Vasc Interv Radiol. 2010 Jul;21(7):995-1003. doi: 10.1016/j.jvir.2010.02.032. Epub 2010 Jun 11.
    Results Reference
    background
    PubMed Identifier
    1839237
    Citation
    Palmaz JC, Encarnacion CE, Garcia OJ, Schatz RA, Rivera FJ, Laborde JC, Dougherty SP. Aortic bifurcation stenosis: treatment with intravascular stents. J Vasc Interv Radiol. 1991 Aug;2(3):319-23. doi: 10.1016/s1051-0443(91)72250-1.
    Results Reference
    background
    PubMed Identifier
    21906903
    Citation
    Mwipatayi BP, Thomas S, Wong J, Temple SE, Vijayan V, Jackson M, Burrows SA; Covered Versus Balloon Expandable Stent Trial (COBEST) Co-investigators. A comparison of covered vs bare expandable stents for the treatment of aortoiliac occlusive disease. J Vasc Surg. 2011 Dec;54(6):1561-70. doi: 10.1016/j.jvs.2011.06.097. Epub 2011 Sep 9.
    Results Reference
    background
    PubMed Identifier
    23640357
    Citation
    Goverde PC, Grimme FA, Verbruggen PJ, Reijnen MM. Covered endovascular reconstruction of aortic bifurcation (CERAB) technique: a new approach in treating extensive aortoiliac occlusive disease. J Cardiovasc Surg (Torino). 2013 Jun;54(3):383-7.
    Results Reference
    background
    PubMed Identifier
    10735428
    Citation
    Saker MB, Oppat WF, Kent SA, Ryu RK, Chrisman HB, Nemcek AA, Pearce W, Pearce W, Vogelzang R. Early failure of aortoiliac kissing stents: histopathologic correlation. J Vasc Interv Radiol. 2000 Mar;11(3):333-6. doi: 10.1016/s1051-0443(07)61426-2. No abstract available.
    Results Reference
    background
    PubMed Identifier
    27012930
    Citation
    Taeymans K, Goverde P, Lauwers K, Verbruggen P. The CERAB technique: tips, tricks and results. J Cardiovasc Surg (Torino). 2016 Jun;57(3):343-9. Epub 2016 Mar 24.
    Results Reference
    background
    PubMed Identifier
    24486037
    Citation
    Groot Jebbink E, Grimme FA, Goverde PC, van Oostayen JA, Slump CH, Reijnen MM. Geometrical consequences of kissing stents and the Covered Endovascular Reconstruction of the Aortic Bifurcation configuration in an in vitro model for endovascular reconstruction of aortic bifurcation. J Vasc Surg. 2015 May;61(5):1306-11. doi: 10.1016/j.jvs.2013.12.026. Epub 2014 Jan 29.
    Results Reference
    background
    PubMed Identifier
    26343310
    Citation
    Grimme FA, Goverde PC, Verbruggen PJ, Zeebregts CJ, Reijnen MM. Editor's Choice--First Results of the Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) Technique for Aortoiliac Occlusive Disease. Eur J Vasc Endovasc Surg. 2015 Nov;50(5):638-47. doi: 10.1016/j.ejvs.2015.06.112. Epub 2015 Sep 3.
    Results Reference
    background
    PubMed Identifier
    9308598
    Citation
    Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, Jones DN. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997 Sep;26(3):517-38. doi: 10.1016/s0741-5214(97)70045-4. Erratum In: J Vasc Surg 2001 Apr;33(4):805.
    Results Reference
    background

    Learn more about this trial

    CERAB Technique for Aortoiliac Occlusive Disease

    We'll reach out to this number within 24 hrs